Precision Oncology - RCC
Renal Cell Carcinoma
DiscoveryActive
Key Facts
About ReviveMed
ReviveMed is a private, pre-revenue biotech company founded in 2017, commercializing an AI and machine learning platform for metabolomics. Its core technology, developed at MIT, addresses key challenges in metabolite signal detection and annotation, enabling the creation of generative models and virtual patient simulations. The company is initially targeting precision obesity and precision oncology, specifically aiming to predict patient response to cancer immunotherapies and better assess metabolic disease risk beyond traditional metrics.
View full company profileTherapeutic Areas
Other Renal Cell Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| XS008 (axitinib) | Xspray Pharma | Preclinical/Development |
| CDK7 allosteric inhibitor | Acellera | Pre-clinical |
| Ciforadenant (CPI-444) | Angel Pharmaceuticals | Phase 1b/2 |
| Lenvatinib (LENVIMA) | Eisai | Regulatory Review |
| Cabozantinib | Exelixis | Phase 3 |
| Zanzalintinib (XL092) | Exelixis | Phase 3 |
| Casdatifan (AB521) | Arcus Biosciences | Phase 3 |
| XmAb®819 | Xencor | Phase 1 |
| MINC‑sunitinib | Suntec Medical | Preclinical |